Ageless Biotech, Inc. Sheridan, WY k'hamphani ea biotech e entsoeng ho tlisa therapeutics e thehiloeng ho stem cell 'marakeng, e fumane US Food and Drug Administration (FDA) Investigational New Drug Application (IND) bakeng sa phekolo ea Osteoarthritis of the Knee.

Arthritis Foundation e hlalositse Osteoarthritis e le "lefu le sa foleng ... le se nang pheko." Lilemong tse leshome tse fetileng ho 2009 ABC News e hatisitsoeng, tlhokomelo ea meriana bakeng sa bakuli ba lefu la masapo a masapo United States e bitsa $ 185.5 limilione tse likete ka selemo.

Ka lilemo tse 4 feela, ho tloha ho 2009 Arthritis Foundation tlaleha litšenyehelo tsa OA USA li imenne habeli joalokaha li phatlalalitsoe ka 2013 ke tlaleho ea CDC ea hore litšenyehelo tsa selemo le selemo tsa Osteoarthritis "e ne e le $ 303.5 limilione tse likete kapa 1% ea 2013 US Gross Domestic Product (GDP) .”

Mopresidente oa Ageless Biotech, Inc, Vince Liguori o bontša, "ho fumanoa ha Stage II OA ea Knee Clinical Trial e re lumella ho qala liteko ka potlako ka merero ea ho qala bofelong ba March 2022. FDA ena e Amoheletsoeng IND e lumella Ageless Biotech ho tlisa sehlahisoa sa Osteoarthritis Stem Cell ho Lingaka le Bakuli ka potlako. ”

Ageless Biotech IND e sebelisa Adipose Derived Stem Cells e se nang li-enzyme kapa lik'hemik'hale tse ling ka mokhoa o tsebahalang o bitsoang Stromal Vascular Fraction (SVF) o etsang matrix a lisele tsa motho tse phelang. Ageless Biotech e rera ho paka thepa ea nchafatso ea Sehlahisoa sa Ageless Biotech SVF pele ho pheletso ea Thuto ena e Amoheletsoeng ea Tleliniki ea FDA ha ka nako e ts'oanang e bonts'a polokeho le nako e fokolang bakeng sa mokuli. Ageless Biotech e lumela hore limilione tsa liopereishene tsa mangole tsa selemo le selemo li tla nkeloa sebaka ke ente e le 'ngoe e bonolo ea lengole. Le hoja re lumela hore theknoloji ena e tla qetella e fuoe lengolo la tumello ho lingaka bakeng sa ho ajoa ka bongata, re ntse re hlahloba ka matla mekhoa e lumellanang le mofuta oa HLA oa "HLA" ho babatsa liphekolo tse joalo nakong e tlang "e seng hole joalo".

Motsamaisi oa Lithekiso oa Naha oa BioXstem, le Setho sa Boto ea Ageless Biotech, Jon Youngs, o boletse hantle ka ho re, "Rōna ba BioXstem re thabile haholo ho ba motseteli ea mafolofolo oa Ageless Biotech hoo joale ha re bue ka eona feela. Re ka re re nka karolo ka mafolofolo ho FDA IND le karolo ea boetapele bo tsoelang pele meriana. ”

SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:

Ageless Biotech plans to prove the regenerative properties of the Ageless Biotech SVF Product before the end of this FDA Accepted Clinical Study while at the same time demonstrating the safety and minimal downtime for a patient.
In just a short 4 years, from the 2009 Arthritis Foundation report the cost of OA in the USA doubled as published in 2013 by the CDC report that annual Osteoarthritis costs “were $303.
The President of Ageless Biotech, Inc, Vince Liguori points out, “the acquisition of a Stage II OA of the Knee Clinical Trial allows us to start trials more rapidly with plans to start by the end of March 2022.